Veradigm | MDRX - Selling And Administration Expenses


Veradigm reported $27.28M in Selling and Administration Expenses for its fiscal quarter ending in December of 2022.





Selling And Administration Expenses Change Date
Alcidion AUD 1.09M 184K Dec/2025
Ambu A/S DKK 684M 5M Mar/2026
Cardinal Health USD 1.51B 6M Mar/2026
Centene USD 3.4B 27M Mar/2026
Charles River Laboratories USD 159.42M 36.71M Mar/2026
Cigna USD 3.32B 291M Mar/2026
Coloplast 2.64B 52M Dec/2025
Convatec Group USD 420.3M 210.35M Dec/2024
Diasorin EUR 56M 49.25M Mar/2026
Elevance Health USD 10.91B 309M Dec/2025
General Electric Aerospace USD 1.08B 496M Mar/2026
Gulf Medical Proj AED 915K 52K Dec/2025
Humana USD 3.36B 614M Mar/2025
IQVIA Holdings USD 502M 34M Mar/2026
Laboratory Of America USD 551M 12.4M Mar/2026
Maximus USD 173.48M 21.32M Mar/2026
McKesson USD 1.8B 234M Mar/2026
Med Life RON 23.07M 3.23M Sep/2025
Molina Healthcare USD 3.77B 2.43B Mar/2026
Omnicell USD 101.99M 5.37M Mar/2026
Oriola-kd EUR 13M 3.1M Sep/2025
Owens Minor USD 258.98M 7.5M Dec/2025
Quest Diagnostics USD 504M 0 Mar/2026
Rede D'or Sao Luiz BRL 145.65M 76.19M Mar/2026
Siemens Healthineers EUR 963M 38M Mar/2026
Sonova Holding CHF 880.2M 300K Jun/2025
Trubridge Inc USD 51.62M 109.74M Dec/2025
UnitedHealth USD 15.22B 1.44B Sep/2025
Veeva Systems USD 126.47M 1.39M Mar/2026
Veradigm USD 27.28M 5.24M Dec/2022
Xerox USD 368M 10M Jun/2025